Avidity Biosciences (RNA) Income towards Parent Company (2019 - 2025)
Historic Income towards Parent Company for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$174.1 million.
- Avidity Biosciences' Income towards Parent Company fell 11712.7% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 9594.62%. This contributed to the annual value of -$322.1 million for FY2024, which is 5218.07% down from last year.
- Avidity Biosciences' Income towards Parent Company amounted to -$174.1 million in Q3 2025, which was down 11712.7% from -$156.7 million recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' Income towards Parent Company registered a high of -$23.8 million during Q1 2021, and its lowest value of -$174.1 million during Q3 2025.
- Moreover, its 5-year median value for Income towards Parent Company was -$52.1 million (2023), whereas its average is -$66.9 million.
- In the last 5 years, Avidity Biosciences' Income towards Parent Company crashed by 29179.95% in 2021 and then tumbled by 257.18% in 2023.
- Quarter analysis of 5 years shows Avidity Biosciences' Income towards Parent Company stood at -$38.5 million in 2021, then tumbled by 31.07% to -$50.5 million in 2022, then dropped by 19.59% to -$60.3 million in 2023, then crashed by 69.81% to -$102.5 million in 2024, then tumbled by 69.89% to -$174.1 million in 2025.
- Its last three reported values are -$174.1 million in Q3 2025, -$156.7 million for Q2 2025, and -$115.3 million during Q1 2025.